0001140361-24-034471.txt : 20240726 0001140361-24-034471.hdr.sgml : 20240726 20240726210533 ACCESSION NUMBER: 0001140361-24-034471 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240724 FILED AS OF DATE: 20240726 DATE AS OF CHANGE: 20240726 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tade Brad L. CENTRAL INDEX KEY: 0002030561 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 241148582 MAIL ADDRESS: STREET 1: 5800 PARK OF COMMERCE BLVD., NW CITY: BOCA RATON STATE: FL ZIP: 33487 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 4 1 form4.xml FORM 4 X0508 4 2024-07-24 0001368514 ADMA BIOLOGICS, INC. ADMA 0002030561 Tade Brad L. C/O ADMA BIOLOGICS, INC. 5800 PARK OF COMMERCE BLVD. NW BOCA RATON FL 33487 true CFO and Treasurer false Common Stock 2024-07-24 4 A 0 72400 0 A 214433 D Stock Option (right to buy) 13.58 2024-07-24 4 A 0 115100 0 A 2034-07-24 Common Stock 115100 115100 D These shares represent restricted stock units ("RSUs") that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan") subject to the reporting person's continued service as of the applicable vesting date. Includes, as of the transaction date, (i) 72,400 RSUs granted on July 24, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 75,000 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; (Continued from Footnote 2 above) (iii) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (iv) 17,033 shares acquired in open market purchases and pursuant to the vesting of RSUs. The options vest over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the grant date. /s/ Brad L. Tade, by Adam S. Grossman as Attorney-in-fact 2024-07-26